These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 28918459)

  • 21. Prognostic role of N-Acetylgalactosaminyltransferase 10 in metastatic renal cell carcinoma.
    Liu L; Xiong Y; Xi W; Wang J; Qu Y; Lin Z; Chen X; Yao J; Xu J; Guo J
    Oncotarget; 2017 Feb; 8(9):14995-15003. PubMed ID: 28122358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted therapy for metastatic renal cell carcinoma.
    Hofmann F; Hwang EC; Lam TB; Bex A; Yuan Y; Marconi LS; Ljungberg B
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012796. PubMed ID: 33058158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors.
    He L; Liu Y; Han H; Liu Z; Huang S; Cao W; Liu B; Qin Z; Guo S; Zhang Z; Lin M; Jiang X; Lin C; Li Y; Yao K; Dong P; Zhou F
    Am J Clin Oncol; 2020 Jan; 43(1):58-63. PubMed ID: 31651452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients.
    Vermaat JS; Gerritse FL; van der Veldt AA; Roessingh WM; Niers TM; Oosting SF; Sleijfer S; Roodhart JM; Beijnen JH; Schellens JH; Gietema JA; Boven E; Richel DJ; Haanen JB; Voest EE
    Eur Urol; 2012 Oct; 62(4):685-95. PubMed ID: 22285764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors.
    Janisch F; Klotzbücher T; Marks P; Kienapfel C; Meyer CP; Yu H; Fühner C; Hillemacher T; Mori K; Mostafei H; Shariat SF; Fisch M; Dahlem R; Rink M
    World J Urol; 2021 Aug; 39(8):2977-2985. PubMed ID: 33649869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Change in platelet count as a prognostic indicator for response to primary tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma.
    Hamilton Z; Lee HJ; Jimenez J; Lane BR; Wang S; Beksac AT; Gillis K; Alagh A; Tobert C; Randall JM; Kane CJ; Millard F; Campbell SC; Derweesh IH
    BJU Int; 2016 Dec; 118(6):927-934. PubMed ID: 27008916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha.
    Dirican A; Kucukzeybek Y; Erten C; Somali I; Demir L; Can A; Payzin KB; Bayoglu IV; Akyol M; Yildiz Y; Koeseoglu M; Alacacioglu A; Tarhan MO
    Asian Pac J Cancer Prev; 2013; 14(3):2101-5. PubMed ID: 23679326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
    Hutson TE; Escudier B; Esteban E; Bjarnason GA; Lim HY; Pittman KB; Senico P; Niethammer A; Lu DR; Hariharan S; Motzer RJ
    J Clin Oncol; 2014 Mar; 32(8):760-7. PubMed ID: 24297950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma.
    Xu X; Zhang S; Wang Y; Zhu Y; Wang J; Guo J
    Cancer Med; 2023 May; 12(9):10512-10525. PubMed ID: 37031459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review.
    Wong MK; Yang H; Signorovitch JE; Wang X; Liu Z; Liu NS; Qi CZ; George DJ
    Curr Med Res Opin; 2014 Apr; 30(4):537-45. PubMed ID: 24329572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SPP1 expression indicates outcome of immunotherapy plus tyrosine kinase inhibition in advanced renal cell carcinoma.
    Xu X; Lin J; Wang J; Wang Y; Zhu Y; Wang J; Guo J
    Hum Vaccin Immunother; 2024 Dec; 20(1):2350101. PubMed ID: 38738709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
    Iacovelli R; Lanoy E; Albiges L; Escudier B
    BJU Int; 2012 Dec; 110(11):1747-53. PubMed ID: 23106948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of galectin-1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma.
    Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
    Cancer Med; 2024 Apr; 13(7):e7113. PubMed ID: 38545824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-targeted therapy.
    Park JY; Lee JL; Baek S; Eo SH; Go H; Ro JY; Cho YM
    Hum Pathol; 2014 Jul; 45(7):1437-44. PubMed ID: 24784922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Body mass index and age are additional prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
    Song Y; Du C; Zhang W; Sun Y; Yang L; Cui C; Chi Y; Shou J; Zhou A; Wang J; Sun Y
    Urol Oncol; 2016 Jun; 34(6):258.e15-22. PubMed ID: 26803435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
    Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
    Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CXCR1 expression predicts benefit from tyrosine kinase inhibitors therapy in patients with metastatic renal cell carcinoma.
    Chen X; Liu L; Wang J; Lin Z; Xiong Y; Qu Y; Wang Z; Yang Y; Guo J; Xu J
    Urol Oncol; 2018 May; 36(5):242.e15-242.e21. PubMed ID: 29370961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?
    Calvani N; Morelli F; Chiuri V; Gnoni A; Scavelli C; Fedele P; Orlando L; Maiello E; Lorusso V; Cinieri S
    Med Oncol; 2013; 30(2):578. PubMed ID: 23613183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients.
    Ivanyi P; Winkler T; Grosshennig A; Reuter C; Merseburger AS; Ganser A; Grünwald V
    World J Urol; 2010 Jun; 28(3):311-7. PubMed ID: 20443009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
    J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.